| Autor: |
Gorgojo-Martínez JJ; Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain., Mezquita-Raya P; Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain., Carretero-Gómez J; Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain., Castro A; Department of Cardiology, University Hospital la Paz, IdiPAZ, Biomedical Research Center-Cardiovascular Diseases (CIBERCV-ISCIII), 28046 Madrid, Spain., Cebrián-Cuenca A; Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain., de Torres-Sánchez A; Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain., García-de-Lucas MD; Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain., Núñez J; Department of Cardiology, Valencia Clinic University Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain., Obaya JC; Health Centre la Chopera, 28100 Madrid, Spain., Soler MJ; Nephrology and Kidney Transplantation Research Group, Nephrology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, 08035 Barcelona, Spain., Górriz JL; Nephrology Department, Valencia Clinic University Hospital, Instituto de Investigación Sanitaria (INCLIVA), Universitat de València, 46010 Valencia, Spain., Rubio-Herrera MÁ; Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain. |
| Abstrakt: |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss. |
